Pioneering RNA Therapeutics for Metabolic Disorders
Canary Cure is at the forefront of medical innovation, leveraging the power of RNA therapeutics to revolutionize the treatment landscape for metabolic disorders. Our cutting-edge pipeline harnesses the potential of gene silencing technology to precisely target the underlying genetic causes of obesity, MASH as well as metabolic dysfunction that impact other diseases.
Unlike first generation therapies that primarily focus on symptom management through appetite suppression, Canary is targeting energy expenditure through the reprogramming of our energy-storing white fat into energy-burning beige fat, prioritizing fat loss, preservation of lean body mass, body composition improvement and overall health.
Delivering Sustained Metabolic Transformation
At the forefront of our pipeline is the first-in-class siRNA therapeutic (CCT-217) engineered to induce sustained metabolic transformation delivering significant weight loss while preserving lean mass and improving liver health with twice-yearly subcutaneous self-dosing. This gene-silencing modifier transforms white fat into metabolically active beige fat, driving sustained weight and fat loss through enhanced energy expenditure.
Our Focus
Nearly every obesity drug on the market works the same way: Suppress appetite, reduce calories, lose weight. The results are temporary. The biology fights back. Muscle is lost. Weight returns. Canary takes a fundamentally different approach. Rather than telling the brain to eat less, we reprogram fat cells themselves — converting inert fat-storing tissue into high-performance, calorie-burning beige adipocytes. The body doesn’t just lose weight, it learns to burn fat as its default state.
The thermogenic revolution in metabolic medicine begins in the adipose tissue, transforming it from storage mode to energy expenditure mode — and Canary has engineered the switch.
Three Disease Areas. One Platform.
Obesity: Unlike conventional approaches, our therapies prioritize fat loss, preservation of lean body mass and body composition improvement. Our novel dual siRNA therapeutics target the energy expenditure systems - promoting the browning of white fat to increase metabolism and facilitate sustainable healthy weight loss. With the convenience of less frequent dosing and better safety profile, this dual gene silencing therapy offers a sustainable biological solution where current therapies only offer temporary suppression.
MASH (Metabolic Dysfunction-Associated Steatohepatitis): By activating the liver’s own fat-burning signals through the adipose endocrine system, our therapies address the underlying metabolic dysfunction driving fatty liver disease and inflammation — without targeting the liver directly.
Rare Metabolic Disease: In conditions where disordered energy metabolism drives pathology, Canary’s ability to re-establish healthy metabolic balance offers a pioneering therapeutic approach for patients with Prader-Willi Syndrome, Hypothalamic Obesity, Bardet-Biedl Syndrome, and Congenital Lipodystrophy. We are developing a dual RNA metabolic restoration platform that directly modulates the gene expression pathways driving these conditions, offering a fundamentally different approach from the symptomatic strategies that families and clinicians currently rely on.
Developing World’s First Treatment for 4H Leukodystrophy
Primarily a pediatric disease, this rare genetic disorder affects the nervous system causing developmental delays, motor difficulties, endocrine issues and other abnormalities. Using mRNA encased in LNP that delivers functional gene directly to affected cells. The goals is to enable the production of healthy protein to halt the progression of the disease and potentially restore function.
Companion Diagnostics for Early Detection and Intervention
In conjunction with our therapeutic efforts, we are also developing novel companion diagnostics that leverage miRNA biomarkers sourced from partner human clinical trials. These diagnostics hold the potential to detect complex diseases and cancers at their earliest stages, enabling timely intervention and maximizing the efficacy of our therapeutic approaches.
Partnering for Progress
We are dedicated to fostering collaborative partnerships that accelerate the development of our transformative therapies. We regularly engage with key partners to share pipeline updates and explore new avenues for therapeutic advancement.
Our Vision: Preserving Human Life
At the heart of our endeavors lies an unwavering commitment to preserving human life. Our pipeline of vectorized gene therapies represents a beacon of hope for individuals facing CNS proteinopathies and rare neurological diseases. We are driven by the unwavering belief that these groundbreaking therapies have the potential to halt disease progression, restore function, and transform the lives of countless individuals.
Canary DigiGENE miRNA Diagnostic overview
Our point of care diagnostic platform uses Al to read miRNA expression patterns in complex diseases at the earliest stages.
Studies have shown a clear distinction in miRNA expression patterns between disease sample and normal healthy samples. This is a heat map of four breast cancer patients showing separation of miRNA expression profiles in tumors and normal tissues.
Obesity and Metabolic Diseases
We are leveraging the power of RNA therapeutics to address the root causes of obesity and metabolic disorders by:
Putting targeted gene-silencing to work to remove the molecular brakes that keep white fat locked in storage mode — activating a self-sustaining cascade of thermogenic fat reprogramming, mitochondrial biogenesis, and systemic metabolic renewal.
Developing World’s First Treatment for 4H Leukodystrophy
Primarily a pediatric disease, this rare genetic disorder affects the nervous system causing developmental delays, motor difficulties, endocrine issues and other abnormalities. Using mRNA encased in LNP that delivers functional gene directly to affected cells. The goals is to enable the production of healthy protein to halt the progression of the disease and potentially restore function.
Companion Diagnostics for Early Detection and Intervention
In conjunction with our therapeutic efforts, we are also developing novel companion diagnostics that leverage miRNA biomarkers sourced from partner human clinical trials. These diagnostics hold the potential to detect complex diseases and cancers at their earliest stages, enabling timely intervention and maximizing the efficacy of our therapeutic approaches.
Partnering for Progress
We are dedicated to fostering collaborative partnerships that accelerate the development of our transformative therapies. We regularly engage with key partners to share pipeline updates and explore new avenues for therapeutic advancement.
Our Vision: Preserving Human Life
At the heart of our endeavors lies an unwavering commitment to preserving human life. Our pipeline of vectorized gene therapies represents a beacon of hope for individuals facing CNS proteinopathies and rare neurological diseases. We are driven by the unwavering belief that these groundbreaking therapies have the potential to halt disease progression, restore function, and transform the lives of countless individuals.
Canary DigiGENE miRNA Diagnostic overview
Our point of care diagnostic platform uses Al to read miRNA expression patterns in complex diseases at the earliest stages.
Studies have shown a clear distinction in miRNA expression patterns between disease sample and normal healthy samples. This is a heat map of four breast cancer patients showing separation of miRNA expression profiles in tumors and normal tissues.
